ATE401392T1 - Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion - Google Patents

Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion

Info

Publication number
ATE401392T1
ATE401392T1 AT05798981T AT05798981T ATE401392T1 AT E401392 T1 ATE401392 T1 AT E401392T1 AT 05798981 T AT05798981 T AT 05798981T AT 05798981 T AT05798981 T AT 05798981T AT E401392 T1 ATE401392 T1 AT E401392T1
Authority
AT
Austria
Prior art keywords
subtype
patients
matched
treatment
inactivated whole
Prior art date
Application number
AT05798981T
Other languages
English (en)
Inventor
Jean-Marie Andrieu
Louis Wei-Lu
Original Assignee
Biovaxim Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovaxim Ltd filed Critical Biovaxim Ltd
Application granted granted Critical
Publication of ATE401392T1 publication Critical patent/ATE401392T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05798981T 2004-10-04 2005-10-04 Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion ATE401392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61572904P 2004-10-04 2004-10-04
US11/243,094 US20060093623A1 (en) 2004-10-04 2005-10-04 Subtype-matched inactivated whole virus vaccines for treating patients with HIV infection

Publications (1)

Publication Number Publication Date
ATE401392T1 true ATE401392T1 (de) 2008-08-15

Family

ID=35695555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05798981T ATE401392T1 (de) 2004-10-04 2005-10-04 Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion

Country Status (14)

Country Link
US (1) US20060093623A1 (de)
EP (1) EP1797175B1 (de)
JP (1) JP2008515795A (de)
CN (1) CN101056977B (de)
AT (1) ATE401392T1 (de)
AU (1) AU2005290930B2 (de)
BR (1) BRPI0516314A (de)
CA (1) CA2582426A1 (de)
DE (1) DE602005008264D1 (de)
ES (1) ES2310848T3 (de)
IL (1) IL182440A (de)
MX (1) MX2007004028A (de)
RU (1) RU2396346C2 (de)
WO (1) WO2006038124A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2558933T3 (es) 2009-01-29 2016-02-09 Michel Vandevelde Composición de vacuna a base de un virus que presenta una proteína con uno o varios restos de dedo de zinc, su procedimiento de preparación y su utilización
US20100216120A1 (en) * 2009-02-23 2010-08-26 Candace Pert Rapid infectious virus assay
DK2694101T3 (en) * 2011-04-06 2017-01-09 Biovaxim Ltd Pharmaceutical compositions for the prevention and / or treatment of HIV disease in humans
HK1204275A1 (en) * 2012-03-02 2015-11-13 Laboratorios Del. Dr. Esteve, S.A. Method for the preparation of dendritic cell vaccines
EP2821082A1 (de) * 2013-07-05 2015-01-07 Laboratoire Biodim Verfahren zur Herstellung eines inaktivierten Lentivirus, insbesondere HIV, Impfstoff, Kit und Verfahren zur Verwendung
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
JP2022539417A (ja) * 2019-07-02 2022-09-08 グリットストーン バイオ インコーポレイテッド Ｈｉｖ抗原及びｍｈｃ複合体
EP4192496A4 (de) 2020-08-06 2025-01-01 Gritstone bio, Inc. Multiepitop-impfstoffkassetten

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE365206T1 (de) * 1998-02-13 2007-07-15 Adan Rios Verfahren zur entwicklung von einem hiv impfstoff
US6828460B2 (en) * 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
CA2397998A1 (en) * 2000-01-28 2001-08-02 Statens Serum Institut Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection
US20040236093A1 (en) * 2001-02-27 2004-11-25 Olivier Schwartz Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro
EP1490396A4 (de) * 2001-03-01 2006-04-19 Us Gov Health & Human Serv Immunogene hiv-peptide zur verwendung als reagentien und impfstoffe
US7566568B2 (en) * 2001-04-27 2009-07-28 Istituto Superiore Di Sanita Method for generating highly active human dendritic cells from peripheral blood mononuclear cells
US20040009194A1 (en) * 2002-06-21 2004-01-15 Jean-Marie Andrieu Methods, and compositions for a therapeutic antigen presenting cell vaccine for treatment of immunodeficiency virus
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
WO2004050855A2 (en) * 2002-12-04 2004-06-17 Baylor Research Institute Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
US7786288B2 (en) * 2003-10-23 2010-08-31 Karp Nelson M Immunizing compositions encoding an epitope obtained from the HIV-1 capsid protein cyclophilin A binding site

Also Published As

Publication number Publication date
JP2008515795A (ja) 2008-05-15
IL182440A0 (en) 2007-07-24
IL182440A (en) 2011-01-31
RU2007115549A (ru) 2008-11-10
CA2582426A1 (en) 2006-04-13
EP1797175B1 (de) 2008-07-16
AU2005290930A1 (en) 2006-04-13
CN101056977A (zh) 2007-10-17
RU2396346C2 (ru) 2010-08-10
CN101056977B (zh) 2013-01-30
MX2007004028A (es) 2007-09-11
AU2005290930B2 (en) 2010-12-16
DE602005008264D1 (de) 2008-08-28
US20060093623A1 (en) 2006-05-04
BRPI0516314A (pt) 2008-09-02
ES2310848T3 (es) 2009-01-16
WO2006038124A1 (en) 2006-04-13
EP1797175A1 (de) 2007-06-20

Similar Documents

Publication Publication Date Title
IL182440A0 (en) Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
MX2018013782A (es) Antigenos y vacunas dirigidos contra enterovirus humanos.
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
EA201490903A1 (ru) Композиции и способы лечения вирусного гепатита c
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
TW200733953A (en) Materials and methods for treating viral infections
ATE452900T1 (de) Impfstoff gegen das west-nile-virus
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
CY1125751T1 (el) Συμπλοκα πρωτεϊνων-πολυμερων
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
UA112970C2 (uk) Інактивований вірус вітряної віспи, спосіб його одержання і застосування
RU2008130825A (ru) Применение экстракта бузины
MX2025012624A (es) Oligonucléotidos para usar en la modulacion de respuestas inmunitarias contra la infección viral de la hepatitis b
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
MX2022007909A (es) Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
WO2021188614A9 (en) Composition, methods of making and using for treating a viral infection, including coronavirus infection
Caruana Old vaccines can fight new pandemics like COVID-19
ZA202402743B (en) Compositions and methods for enhancing and expanding infection induced immunity
HRP20030701A2 (en) Natural antibodies active against hiv virus
MX2023011177A (es) Nueva aplicación de una composición inmunogénica o de vacuna.
ATE475426T1 (de) Behandlung oder prävention von hämorrhagischen virusinfektionen mit immunomodulatorischen verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties